MPc3_CBX8 Inhibitors
Chemical inhibitors of MPc3 can exert their inhibitory effects through the disruption of cell cycle regulation, given that MPc3's function is closely associated with cell cycle control. Compounds such as PD 0332991, Ribociclib, and Abemaciclib are all classified as CDK4/6 inhibitors, which directly target enzymes critical for the phosphorylation of the retinoblastoma protein (Rb). This phosphorylation event is a prerequisite for cell cycle progression from the G1 to the S phase, an area where MPc3 is known to operate. By inhibiting CDK4/6, these chemicals effectively induce G1 phase arrest, thereby curtailing the cellular context in which MPc3 exerts its function, leading to its functional inhibition. Similarly, Olomoucine and Roscovitine specifically target a range of CDKs including CDK1, CDK2, and CDK5, further contributing to cell cycle arrest and hence the functional inhibition of MPc3 by impeding the progression of phases that MPc3 is reliant upon.
Alsterpaullone and Purvalanol A, which are potent inhibitors of CDK1 and CDK2, also contribute to the impediment of cell cycle progression, thereby indirectly inhibiting the activity of MPc3. On the other hand, Dinaciclib and Milciclib broaden the scope of inhibition to include other CDKs and kinases like TrkA, which affect not only the cell cycle but also transcription regulation. This broad-spectrum inhibition disrupts cellular processes that are essential for MPc3's activity. Flavopiridol, by inhibiting CDKs, particularly affects transcription regulation that is linked to cell cycle progression, further contributing to the functional inhibition of MPc3. SNS-032 and AZD5438 extend this inhibition to CDKs that are crucial for both cell cycle transitions and transcription machinery, thereby creating a cellular environment that is non-conducive for MPc3 activity, leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits cyclin-dependent kinases (CDKs) 4 and 6, which may lead to a reduction in the phosphorylation of the retinoblastoma (Rb) protein, a process MPc3 is involved in. This inhibition restricts cell cycle progression from G1 to S phase, consequently inhibiting MPc3 which is associated with cell cycle regulation. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Like Palbociclib, Ribociclib selectively inhibits CDK4/6, diminishing Rb phosphorylation. This results in G1 phase arrest and indirectly inhibits MPc3 activity by limiting the cellular context in which MPc3 operates within the cell cycle. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is another CDK4/6 inhibitor that leads to decreased Rb phosphorylation. By halting G1 to S phase progression, it indirectly inhibits MPc3 by impairing the cell cycle context in which MPc3 acts. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDKs, including CDK1, CDK2, and CDK5. By inhibiting these kinases, it disrupts cell cycle progression, thereby indirectly inhibiting MPc3 which is linked to cell cycle control. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine specifically inhibits CDKs 1, 2, 5, 7, and 9. This broad spectrum of inhibition affects multiple phases of the cell cycle, indirectly inhibiting MPc3 by obstructing the cell cycle-dependent pathways it is involved in. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a potent inhibitor of CDK1 and CDK2. By obstructing these kinases' activity, it interferes with cell cycle progression, thus indirectly inhibiting MPc3's cell cycle-associated functions. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a potent inhibitor of CDKs, especially CDK1, CDK2, and CDK5. This inhibition of CDK activity leads to a disruption in cell cycle control, thereby indirectly inhibiting MPc3, which is contingent upon cell cycle phases for its activity. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib strongly inhibits CDKs 1, 2, 5, and 9. This broad inhibition affects the cell cycle and transcription regulation, indirectly inhibiting MPc3's activity related to these processes. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib targets multiple CDKs and also tropomyosin receptor kinase A (TrkA). By blocking CDKs involved in cell cycle regulation, it indirectly inhibits MPc3 by disrupting the cellular processes MPc3 is involved in. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits CDKs and can induce cell cycle arrest. This inhibition indirectly affects MPc3 by impeding the cell cycle machinery that MPc3 is associated with, particularly impacting transcription regulation related to cell cycle progression. | ||||||